BioNTech and Bristol Myers Squibb report punchy early results for experimental TNBC therapy

The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first

AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment

Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected

Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial

It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)

Bayer reports promising results for low-dose pediatric MRI contrast agent

MRI is particularly valuable in pediatric care due to its non-invasive nature

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

AbbVie’s Atogepant shows breakthrough results for acute migraine relief

Suffering from acute migraine? You may soon bid adieu to the debilitating headache

Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial

Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance